Top AI Healthcare Stocks For September 2026

Oil prices linked to US Iran risks are feeding into higher inflation expectations and government bond yields. That puts pressure on healthcare budgets and insurance costs, which makes smarter, more efficient care especially valuable. Artificial intelligence in healthcare targets that problem by using data, automation and remote monitoring to do more with less. This article walks through 3 stocks from our AI healthcare screener that illustrate how that theme is playing out.

The three stocks below are just a sample from this theme, and the full screen surfaced 35 more AI healthcare companies with equally compelling investment narratives that are not covered in the article. If you want to move beyond the highlights and identify which AI healthcare opportunities best fit your profile, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Pfizer (PFE)

Overview: Pfizer is a global biopharmaceutical company that discovers and sells prescription medicines and vaccines across areas such as cardiovascular disease, migraines, COVID-19, rare diseases and cancer. Alongside this broad portfolio, Pfizer is investing in biomolecular AI foundation models through its Boltz collaboration and internal AI tools to speed drug discovery, refine clinical trials and make its pipeline more targeted.

Operations: Pfizer generates about US$62.3b in revenue primarily from its Global Biopharmaceuticals Business segment, with roughly US$37.4b from the United States, US$9.5b from emerging markets and US$16.8b from other developed markets.

Market Cap: US$162.2b

Investors watching how AI reshapes healthcare may want to keep Pfizer on the radar, because its collaboration with Boltz and internal biomolecular AI programs give it a direct shot at faster, cheaper and more targeted drug development across a very broad pipeline in oncology, vaccines and obesity. The scale of Pfizer’s data, its acquisitions in areas such as cancer, and its focus on digitalization create conditions for AI to influence R&D productivity and margins over time. At the same time, debt, dividend coverage and patent expiries remain important pressure points.

Pfizer’s push into biomolecular AI could reshape how its US$62.3b in annual revenue is earned, yet the real story sits in the fine print of its pipeline, debt profile and patent clock. Before you decide how that balance of promise and pressure fits your portfolio, scan the 2 key rewards and 4 important warning signs

Tempus AI (TEM)

Overview: Tempus AI is a healthcare technology company that uses its Next AI platform and genomics based diagnostics to turn multimodal clinical, molecular, imaging, and ECG data into decision tools for doctors, researchers, and drug developers, with applications that range from precision oncology and inherited disease testing to AI driven clinical trial matching and cardiovascular risk detection.

Operations: Tempus AI generates about US$1.4b in revenue from its Medical Labs and Research activities in the United States.

Market Cap: US$11.4b

Tempus AI offers direct exposure to an AI in healthcare strategy, where each new genomic test, ECG analysis, and data licensing deal can contribute to a larger, more powerful dataset and smarter clinical algorithms. Recent FDA clearances for cardiovascular AI tools, high profile oncology collaborations, and a growing portfolio of multimodal models illustrate how that data flywheel can translate into new services and pharma relationships. At the same time, a premium valuation, ongoing losses, and insider selling highlight execution risk. The company’s ability to use its scale in de identified data and AI diagnostics to drive customer demand and improve profitability will be an important factor in how this model develops.

Tempus AI’s data flywheel is accelerating, but the real story lies in how that momentum interacts with its valuation, losses, and insider selling. Get the full picture in the analysis report for Tempus AI

Medtronic (MDT)

Overview: Medtronic is a global medical device company that supplies hospitals and clinicians with products ranging from cardiac implants and neuromodulation systems to an AI powered surgical video and analytics platform that helps surgeons make better decisions in the operating room. Its diversified Cardiovascular, Neuroscience, and Medical Surgical portfolios give Medtronic broad exposure to chronic disease treatment, while its AI and robotics tools aim to improve outcomes and efficiency during complex procedures.

Market Cap: US$116.0b

Medtronic gives you a way to tap into AI in the operating room, where its surgical video analytics, spine AiBLE planning tools, and expanding robotics ecosystem aim to cut complications, shorten procedures, and lower costs for hospitals. Analysts expect earnings and margins to improve as new ablation systems, robotic platforms, and digital health tools roll out. A long history in cardiac and neurosurgical hardware provides scale and cash flow support. The trade off is that AI driven products are still a smaller part of revenue, some segments such as Diabetes and parts of MedSurg are under pressure, and newer management must prove it can turn heavy R&D spending into sustainable growth.

Medtronic’s push into AI guided surgery and robotics could be masking a very different earnings path than many investors assume. Before the rest of the market joins the story, review the analyst forecasts for Medtronic

Seeking Fresh Alternatives Beyond AI Healthcare

Fresh stock ideas can move from quiet to flying once momentum builds. Use these curated screens before the crowd catches on and the best entry points are gone.

• Target resilient compounders by reviewing a curated list of solid balance sheet and fundamentals (53 results) that can help you focus on companies with stronger fundamentals while prices still look reasonable.
• Ride long term infrastructure momentum by checking the hand picked 39 power grid technology and infrastructure stocks that highlights businesses tied to grid upgrades while they remain under the radar for now.
• Position for the AI backbone by scanning the focused 55 AI infrastructure stocks curated list so you are not caught chasing prices after the next breakout.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com